Veradermics' topical VDPHL01 demonstrated measurable hair regrowth in women with androgenetic alopecia, producing mean increases of 22–23 hairs/cm² at six months and improvement in hair coverage in nearly 90% of participants, with no serious safety signals. These Phase 2 findings support advancement toward confirmatory trials and represent a potential treatment option for female pattern hair loss, where therapeutic options remain limited.
Key Points
- 22–23 hairs/cm² increase at month 6 across dosing regimens
- 89–90% of participants achieved improved hair coverage by month 6
- No serious adverse events or cardiac safety signals observed
Longevity Analysis
Female pattern hair loss reflects systemic changes in how the body regulates hormonal signaling and maintains tissue regeneration—processes that become increasingly dysregulated across the lifespan. A topical treatment that restores hair growth without systemic safety burden addresses both the cosmetic and deeper physiological dimensions of aging. Success at this stage narrows the gap between mechanistic understanding of androgenetic alopecia and accessible clinical intervention, enabling practitioners to support one visible marker of cellular and hormonal health in women for whom current options are sparse.
Original published by LT Wire.